Netherlands-based Mylan said it also intends to continue to market and distribute branded EpiPen.
Advertisement
But they’re not convinced this is a great deal either. But it will have a wholesale list price of $300 for a pack of two, half the price of the brand-name EpiPen.
But days later, in an apparent about-face, Mylan said on its website that it was reducing the cost of its EpiPens through a savings card which will cover up to $300 for the two-pack.
Long claimed Schumer’s committee had received $238,000 from the pharmaceutical industry’s PACs since 2004, and $195,000 from individual drug-industry donors since 1999.
We urge lawmakers and regulators to step in and shine a light on the true development and production costs of pharmaceuticals. But pharmacists say co-pay cards can not be used to purchase generic drugs, so essentially patients will still be paying $300. It will be available in both 0.15-milligram and 0.30-milligram strengths, as is the current version on the market.
Porter said he wanted to buy three sets of EpiPens to keep in their cars and at home, but he said it’s more than $300 for him to purchase the device in the United States. “The problem is in a crisis situation that’s nearly impossible for a parent or a child to be able to successfully do that”, said Friedman.
The price of the EpiPen, which treats anaphylaxis, has risen sixfold in recent years, and the widespread anger seems to stem from the opacity of the reasons why. That cuts out the wholesalers and the pharmacy benefit managers, which are in charge of negotiating drug prices, along with the charges that would come along with their involvement. On Thursday, Mylan reduced out-of-pocket costs of EpiPen for some patients, but kept the list price steady at roughly $600.
“I forgot my purse recently and I realized I didn’t have the EpiPens so I turned around because I don’t know what he might touch”, said Schuller-Meyer. To minimize this, Mylan has launched the generic version of the branded injection which has provided them with great commercial response. In October, Sanofi voluntarily recalled its Auvi-Q injector from the market over concerns about suspected malfunctions in the US and Canada. So now, the company will essentially sell the same product under two names at two price points, in competition with each other.
“I think basically anything we can do to get prescription drug prices down-I think all prescription drug prices are extremely high”, Manchin said.
Advertisement
“Alaskans want to hear directly from the company, under oath, exactly how a 400 percent or more price increase for an off-patent medication is justifiable”, she said in statement accompanying the release of the letter.
